A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients

Part of paid clinical trials in Jacksonville, Florida.

Sponsor
Mayo Clinic
Study ID
NCT05803551
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • Ketamine Hydrochloride — DRUG
    Intravenous 0.5 mg/kg infusions of ketamine for three consecutive days, 24 hours apart, with no more than 1mg/kg or 60 mg/day regardless of body weight
  • Placebo — DRUG
    Intravenous 0.9% saline infusions for three consecutive days.

Study Details

The purpose of this research is to study the effects of intravenous ketamine infusions for the treatment of patients with depressive symptoms in intensive care unit (ICU).

Key Dates

Start date
Jul 7, 2025
Status verified
Aug 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Ketamine Group
    Adult patients who have been in the Mayo Clinic Florida ICU for one week with moderate or severe depression will receive intravenous (IV) ketamine
  • Placebo Comparator: Placebo Group
    Adult patients who have been in the Mayo Clinic Florida ICU for one week with moderate or severe depression will receive intravenous (IV) placebo

Primary Outcome Measure

Change in depressive symptoms [ Time Frame: Baseline, 7 days after third infusion ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic FloridaJacksonvilleFlorida32224
Devang Sanghavi
[email protected]
3146408772

Find similar trials in Jacksonville, FL

By condition
Depression
By specialty
PsychiatryMental healthBehavioral health
By research site
Mayo Clinic Florida· Jacksonville, FL

Related Studies